2,6-di-O-Galloylarbutin



Compound IDCDAMM02753
Common name2,6-di-O-Galloylarbutin
IUPAC name[3,4-dihydroxy-6-(4-hydroxyphenoxy)-5-(3,4,5-trihydroxybenzoyl)oxyoxan-2-yl]methyl 3,4,5-trihydroxybenzoate
Molecular formulaC26H24O15

Experimental data

Retention time12.54
Adduct[M+H]+
Actual mz577.121
Theoretical mz577.119
Error3.33
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.2759

Identifiers and class information

Inchi keyQACZCPQDYIUXRV-VKGKZTBONA-N
SmilesO=C(OCC1OC(OC2=CC=C(O)C=C2)C(OC(=O)C3=CC(O)=C(O)C(O)=C3)C(O)C1O)C4=CC(O)=C(O)C(O)=C4
SuperclassOrganic oxygen compounds
ClassOrganooxygen compounds

Pharmacokinetic properties

Number of descriptor values(#stars)8
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)16
Number of reactive functional groups (#rtvFG)3
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)576.467
Computed dipole moment(dipole)7.186
Total solvent accessible surface area (SASA)873.32
Hydrophobic component of SASA (FOSA)91.776
Hydrophilic component of SASA (FISA)489.583
Pie component of the SASA (PISA)291.961
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1590.17
Number of hydrogen bond donors (donorHB)9
Number of hydrogen bond acceptors (accptHB)15.1
Free energy of solvation of dipole (dip^2/V)0.0324738
Index of cohesive interaction in solids (ACxDN^.5/SA)0.051871
Globularity descriptor (glob)0.754434
Predicted polarizability in cubic angstroms (QPpolrz)49.999
Predicted hexadecane/gas partition coefficient (QPlogPC16)20.872
Predicted octanol/gas partition coefficient (QPlogPoct)39.64
Predicted water/gas partition coefficient (QPlogPw)31.662
Predicted octanol/water partition coefficient (QPlogPo/w)-1.129
Predicted aqueous solubility (QPlogS)-3.826
Conformation-independent predicted aqueous solubility (CIQPlogS)-5.499
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.898
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)0.226
Predicted brain/blood partition coefficient (QPlogBB)-6.135
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.057
Predicted skin permeability, log Kp (QPlogKp)-7.978
PM3 calculated ionization potential (IP(ev))8.846
PM3 calculated electron affinity (EA(eV))0.744
Number of likely metabolic reactions (#metab)9
Prediction of binding to human serum albumin (QPlogKhsa)-0.898
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)274.802
Number of nitrogen and oxygen atoms (#NandO)15
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P17612PRKACAcAMP-dependent protein kinase alpha-catalytic subunitT12808SEA
P05121SERPINE1Plasminogen activator inhibitor-1T15556SEA
P24723PRKCHProtein kinase C etaT40149SEA
P05771PRKCBProtein kinase C betaT40276SEA
Q02156PRKCEProtein kinase C epsilonT00895SEA
P60568IL2Interleukin-2T61698SEA
Q9NUW8TDP1Tyrosyl-DNA phosphodiesterase 1T33492SwissTargetPrediction and SEA
P17931LGALS3Galectin-3T72038SEA
P14679TYRTyrosinaseT97035SEA
Q9GZQ4NMUR2Neuromedin-U receptor 2T04210SEA
P52209PGD6-phosphogluconate dehydrogenaseT76497SEA
P05129PRKCGProtein kinase C gammaT47107SEA
P63316TNNC1Troponin, cardiac muscleT12966SEA
P09382LGALS1Galectin-1T09544SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
Q99417MYCBPMYCBP messenger RNAT37298SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA
P19429TNNI3Cardiac troponin IT20186SEA
P45379TNNT2Cardiac muscle troponin TT05887SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T12808DI0279Muscular atrophy[ICD-11: 8B61]P17612PRKACA
T15556DI0037Asthma[ICD-11: CA23]P05121SERPINE1
T15556DI0405Thrombosis[ICD-11: DB61-GB90]P05121SERPINE1
T40149DI0184Human immunodeficiency virus disease[ICD-11: 1C60-1C62]P24723PRKCH
T40276DI0123Diffuse large B-cell lymphoma[ICD-11: 2A81]P05771PRKCB
T40276DI0241Lymphoma[ICD-11: 2A80-2A86]P05771PRKCB
T40276DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]P05771PRKCB
T00895DI0033Anxiety disorder[ICD-11: 6B00-6B0Z]Q02156PRKCE
T00895DI0243Malaria[ICD-11: 1F40-1F45]Q02156PRKCE
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T76497DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P52209PGD
T47107DI0012Acute myeloid leukaemia[ICD-11: 2A60]P05129PRKCG
T47107DI0248Mastocytosis[ICD-11: 2A21]P05129PRKCG
T12966DI0006Acquired cutaneous blood vessel malformation[ICD-11: EF20]P63316TNNC1
T12966DI0175Heart failure[ICD-11: BD10-BD1Z]P63316TNNC1
T37298DI0235Liver cancer[ICD-11: 2C12]Q99417MYCBP
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025